About Northstar Study
The Northstar Study (HGB-204), a Phase 1/2 study, is fully enrolled and is in the follow-up phase of the study. Early data
from the Northstar Study shows that patients with non-β0
genotypes and ≥12 months of follow up have stopped regular transfusions; patients with β0
genotypes and ≥12 months of follow up had a median reduction in transfusion volume of 63%.